SCHEDULE: Stonepine Capital Maintains 9.9% Stake in Aytu BioPharma
Beneficial Ownership Disclosure
Stonepine Capital Management and its affiliates disclosed a continued 9.9% beneficial ownership stake in Aytu BioPharma, Inc., comprising common stock and various warrants.
Summary
- Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico collectively beneficially own 906,063 shares of Aytu BioPharma, Inc. common stock.
- This represents 9.9% of the company's outstanding common stock.
- The beneficial ownership includes 812,676 shares of common stock, Prefunded Warrants to acquire 2,446,883 shares, Tranche A Warrants to acquire 815,217 shares, and Tranche B Warrants to acquire 815,217 shares.
- The Prefunded, Tranche A, and Tranche B Warrants are each subject to a 9.99% beneficial ownership limitation, restricting their exercise if it would result in ownership exceeding this threshold.
- The reported percentage is calculated based on 8,976,314 shares of Common Stock outstanding as of June 9, 2025, as reported in the company's Form 8-K.
Sentiment
Score: 6
Explanation: The filing indicates a continued significant stake by an institutional investor, which can be seen as a neutral to slightly positive signal of ongoing interest, but it does not provide new performance data or strategic updates.
Positives
- Continued significant investment by Stonepine Capital and its affiliates, indicating ongoing interest in Aytu BioPharma.
- The beneficial ownership limitation on warrants prevents immediate dilution from full exercise, maintaining the current ownership percentage.
Risks
- The beneficial ownership limitation of 9.99% on the warrants restricts the reporting persons from acquiring more than this percentage of the common stock through warrant exercise, which could limit their ability to increase their stake or influence.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-06-09 | Date of Common Stock outstanding calculation (8,976,314 shares) as reported in Form 8-K. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-13 | Filing date of the Schedule 13G Amendment No. 3. |
Keywords
Aytu BioPharma, AYTU, Stonepine Capital, Schedule 13G, beneficial ownership, common stock, warrants, biopharma, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.